Form 4: Apellis R&D Chief Awarded Significant Equity

Apellis Pharmaceuticals' Chief Research and Development Officer, Leslie Meltzer, received significant equity awards, including restricted stock units and stock options, on August 26, 2025.

Summary

• On August 26, 2025, Leslie Meltzer, Chief Research and Development at Apellis Pharmaceuticals, Inc. (APLS), was granted equity awards.
• She received 61,804 Restricted Stock Units (RSUs), which will vest 25% annually over four years from the grant date, subject to her continued service.
• Additionally, she was awarded 92,592 stock options with an exercise price of $16.2.
• These stock options vest 25% one year from the grant date, with the remaining 75% vesting monthly thereafter, subject to continued service, and expire on August 26, 2035.
• The Form 4 reporting these transactions was signed on September 2, 2025.

Sentiment

Score: 7

Explanation: The grant of significant equity awards to a key executive is a positive signal for executive retention and alignment of interests with shareholders, reflecting confidence in the individual's continued contribution to the company's future.

Positives

• Significant equity awards granted to a key executive, Leslie Meltzer, aligning her interests with long-term shareholder value.
• The awards incentivize continued service and performance over a four-year vesting period, promoting executive retention.

Future Outlook

The equity awards are structured to incentivize Leslie Meltzer's continued service and performance over the next four years, aligning her long-term commitment with the company's strategic objectives.

Industry Context

Equity grants are standard practice in the biotech and pharmaceutical industry to attract and retain top talent, especially in critical research and development roles, by aligning executive compensation with long-term company performance and shareholder value creation.

Comparison to Industry Standards

• Equity compensation packages for Chief R&D Officers in the pharmaceutical industry often include a mix of RSUs and stock options, with multi-year vesting schedules (typically 3-5 years) to ensure long-term retention and alignment with company performance.
• The size of the grant (over 150,000 total equity instruments) is substantial and competitive for a Chief R&D role at a publicly traded pharmaceutical company like Apellis, comparable to grants seen at companies such as BioMarin Pharmaceutical Inc. or Sarepta Therapeutics, Inc. for similar executive levels, reflecting the high value placed on leadership in drug discovery and development.

Stakeholder Impact

• Shareholders: Positive, as it aligns executive interests with long-term shareholder value and incentivizes performance.
• Employees: May signal stability in leadership and a commitment to retaining key talent within the company.

Next Steps

• Continued service by Leslie Meltzer to fulfill the vesting conditions of the restricted stock units and stock options.
• Future reporting of any changes in beneficial ownership by Leslie Meltzer as required by SEC regulations.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a key executive, which is a standard component of executive compensation. While it aligns management's interests with long-term shareholder value, it does not provide new operational or financial information that would fundamentally alter the investment thesis for Apellis Pharmaceuticals. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals and market conditions.

Keywords

Apellis Pharmaceuticals, APLS, Leslie Meltzer, Form 4, equity award, restricted stock units, stock options, executive compensation, insider transaction